2016 New Therapeutics in Oncology

Expert Point of View: Barry E. Rosenbloom, MD

Moderator of the session, Barry E. Rosenbloom, MD, Clinical Professor of Medicine at Tower Hematology Oncology Medical Group in Los Angeles, said that the overview of recent advances in lung cancer c...

Lung Cancer

New Treatments for Lung Cancer in 2016

With drug approvals for immunotherapy in the first- and second-line settings, breakthroughs in targeting epidermal growth factor receptor (EGFR) mutations, and the rapid evolution of therapies that ta...

CNS Cancers

Expert Point of View: Steven Piantadosi, MD, PhD

In an interview with The ASCO Post, Steven Piantadosi, MD, PhD, Professor of Medicine and Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai in Los Angeles, expressed enthus...

CNS Cancers

Bad Year for Brain Tumors, but Still Reasons for Hope

Checkpoint inhibitors and targeted therapies are reshaping the landscape of cancer care across multiple tumor sites, but treatments for brain tumors remain decidedly unchanged. The standard of care fo...

Solid Tumors

Mutanome-Directed Immunotherapy: Finding the Best Treatment Match

Oncologists may be accustomed to looking for commonalities in patients, but highly personalized therapies are now being developed based on mutational analysis of tumors. According to data presented at...

Advertisement

Advertisement



Advertisement